SAN DIEGO, June 25, 2024 /PRNewswire/ -- NXTSTIM will
present their 18-month real-world outcomes data using
EcoAI™ at the American Society of Pain and
Neuroscience 6th annual conference, July
11-14th, 2024, in Miami,
Florida, USA. EcoAI, developed by NXTSTIM, is a novel,
wearable, smart device incorporating transcutaneous electrical
nerve and electromyographic stimulation. This device works on a
closed-loop function with personalized pain-tracking, remote
patient monitoring (RPM), and continuous optimization features
using artificial intelligence machine learning (AIML)
technology.
A large real-world cohort of 550 adult patients (18 years
of age or older) were included in the study. The most common sites
of therapy were for back pain, neck pain, shoulder pain, and knee
pain. Other sites included pain of focal neurologic origin. After
over 18 months of usage, 92% of patients reported pain improvement
compared to baseline scores. Of these 550 adult patients, 66%
demonstrated at least a 40% improvement in visual analog pain scale
scores compared to baseline. No adverse events were
reported.
"This is the first large real-world demonstration of using
the EcoAI AIML technology combined with remote patient monitoring
(RPM) to show durable outcomes. With no adverse events reported and
significant pain relief in over 66% of patients out to 18 months,
this is a landmark approach to pain care using a front-end
electroceutical solution," said Prachi
Patel MD on behalf of study investigators.
"NXTSTIM has been pioneering the incorporation of remote
patient monitoring into the pain space. By using proprietary AI
technology and over 30 different stimulation parameters, we are
showing that we can devise a front-end electroceutical device that
can also serve as an excellent remote patient monitoring (RPM)
tool. The significance of our durable data opens a new treatment
algorithm to pain management clinicians globally," said
Krishnan Chakravarthy MD, PhD,
Founder and CEO.
About NXTSTIM: NXTSTIM – "Next
Generation Stimulation Technologies" was founded by Krishnan Chakravarthy MD, PhD in 2020. NXTSTIM
is an American neuromodulation and biotechnology company based in
San Diego, California,
United States. NXTSTIM designs and
manufactures medical devices using novel battery technology,
digital software platforms, and related products and services.
Learn more at www.nxtstim.com.
Contact:
Andree Kaminsky
Director of Communications
NXTSTIM
Phone: (917) 324-5215
Email: andree@nxtstim.com
View original
content:https://www.prnewswire.com/news-releases/nxtstim-ecoai-using-novel-artificial-intelligence-machine-learning-aiml-technology-with-transcutaneous-nerve-and-electromyographic-stimulation-shows-outstanding-18-month-real-world-outcomes-data-with-a-remote-patient-monitoring-302179772.html
SOURCE NXTSTIM